This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).
Give signed written informed consent to participate.
At least 40 years of age at baseline visit.
Previous or newly diagnosed by at least one of the 3 types of CVD which are,
Coronary heart disease ( CHD )
Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study.
Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
Participant who are not able to provide written informed consent.
Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.
Single group
Guideline education and implementation intervention
BehavioralThe intervention is implemented at the investigator level and the patient level, consisted of 3 parts： 1. Disease education * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled. * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study. 2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD. 3. Follow-up management:the subjects will be followed up every 4 weeks.
The number and percentage of COPD in participants with CVD,CHD,AF,CHF.
To describe the prevalence of COPD in participants with CVD.
The hospitalization/readmission rate in participants with COPD.
To describe the hospitalization/readmission rate in participants with COPD during the implementation of cardiopulmonary co-management.
The hospitalization/readmission rate in CHD, AF and CHF participants with COPD.
To describe the hospitalization/readmission rate in participants with CVD during the implementation of cardiopulmonary co-management.
Change from baseline in SAQ score in participants with CHD and COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
Change from baseline in AFEQT score in participants with AF and COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
The exacerbation rate in CVD, CHD, AF and CHF participants with COPD over 12 weeks.
To explore the exacerbation rate in participants with CVD and COPD during the period of cardiopulmonary co-management.
Rate of MACE in CVD, CHD, AF and CHF participants with COPD over 12 weeks.
To explore the occurrence of MACE event in participants with CVD and COPD during the period of cardiopulmonary co-management.
Rate of differente types of MACE in CVD, CHD, AF and CHF participants with COPD over 12 weeks.
To explore the occurrence of MACE event in participants with CVD and COPD during the period of cardiopulmonary co-management.
Risk factors for COPD diagnosis in CHD, AF and CHF participants (analysis scope includes demographics, physiological data, family history, smoking status, age, comorbidities, lung function parameters, biomarkers, etc.)
To explore the risk factors in CVD participants with COPD.
Click on the lead sponsor to view all of their trials.
